193 related articles for article (PubMed ID: 35056955)
1. In Silico Screening of Available Drugs Targeting Non-Small Cell Lung Cancer Targets: A Drug Repurposing Approach.
Thirunavukkarasu MK; Suriya U; Rungrotmongkol T; Karuppasamy R
Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056955
[TBL] [Abstract][Full Text] [Related]
2. Drug repurposing combined with MM/PBSA based validation strategies towards MEK inhibitors screening.
Thirunavukkarasu MK; Karuppasamy R
J Biomol Struct Dyn; 2022; 40(22):12392-12403. PubMed ID: 34459701
[TBL] [Abstract][Full Text] [Related]
3. Sequential virtual screening collaborated with machine-learning strategies for the discovery of precise medicine against non-small cell lung cancer.
Thirunavukkarasu MK; Veerappapillai S; Karuppasamy R
J Biomol Struct Dyn; 2024; 42(2):615-628. PubMed ID: 36995235
[TBL] [Abstract][Full Text] [Related]
4. Computational biophysics approach towards the discovery of multi-kinase blockers for the management of MAPK pathway dysregulation.
Thirunavukkarasu MK; Veerappapillai S; Karuppasamy R
Mol Divers; 2023 Oct; 27(5):2093-2110. PubMed ID: 36260173
[TBL] [Abstract][Full Text] [Related]
5. Exploring safe and potent bioactives for the treatment of non-small cell lung cancer.
Thirunavukkarasu MK; Shin WH; Karuppasamy R
3 Biotech; 2021 May; 11(5):241. PubMed ID: 33968584
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a Potent Candidate for RET-Specific Non-Small-Cell Lung Cancer-A Combined In Silico and In Vitro Strategy.
Ramesh P; Shin WH; Veerappapillai S
Pharmaceutics; 2021 Oct; 13(11):. PubMed ID: 34834190
[TBL] [Abstract][Full Text] [Related]
7. Identification of Antimycobacterial Agent Using In Silico Virtual Screening, ADME Prediction, Docking, and Molecular Dynamics Simulations Approach.
Tripathy S; Sahu SK; Azam MA; Jupudi S; Gupta VK; Sharma S
Curr Comput Aided Drug Des; 2021; 17(6):806-816. PubMed ID: 32748754
[TBL] [Abstract][Full Text] [Related]
8. Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents.
Ahmed MZ; Zia Q; Haque A; Alqahtani AS; Almarfadi OM; Banawas S; Alqahtani MS; Ameta KL; Haque S
J Infect Public Health; 2021 May; 14(5):611-619. PubMed ID: 33866129
[TBL] [Abstract][Full Text] [Related]
9. Identification of potential inhibitors against
Gaur V; Kumar N; Vyas A; Chowdhury D; Singh J; Bera S
J Biomol Struct Dyn; 2023 Dec; ():1-11. PubMed ID: 38149858
[TBL] [Abstract][Full Text] [Related]
10. Integrated computational approach for
Kuchana V; Kashetti V; Peddi SKR; Sivan S; Manga V
J Recept Signal Transduct Res; 2022 Oct; 42(5):439-453. PubMed ID: 34844526
[TBL] [Abstract][Full Text] [Related]
11.
Bouricha EM; Hakmi M; Akachar J; Zouaidia F; Ibrahimi A
J Biomol Struct Dyn; 2022 Jul; 40(11):5203-5210. PubMed ID: 33402049
[TBL] [Abstract][Full Text] [Related]
12. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
Ebrahimi M; Karami L; Alijanianzadeh M
Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
[TBL] [Abstract][Full Text] [Related]
13. Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease.
Chowdhury KH; Chowdhury MR; Mahmud S; Tareq AM; Hanif NB; Banu N; Reza ASMA; Emran TB; Simal-Gandara J
Biology (Basel); 2020 Dec; 10(1):. PubMed ID: 33374717
[TBL] [Abstract][Full Text] [Related]
14. Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification.
Wang Y; He X; Li C; Ma Y; Xue W; Hu B; Wang J; Zhang T; Zhang F
Eur J Med Chem; 2020 May; 193():112235. PubMed ID: 32203789
[TBL] [Abstract][Full Text] [Related]
15. Integrating Ligand and Target-Driven Based Virtual Screening Approaches With
Tutumlu G; Dogan B; Avsar T; Orhan MD; Calis S; Durdagi S
Front Chem; 2020; 8():167. PubMed ID: 32328476
[TBL] [Abstract][Full Text] [Related]
16. Identification of Multi-kinase Allosteric Inhibitors of Oncogenic Targets EGFR1, PI3K, and BRAF Kinase.
Kakarala KK; Jamil K
Curr Comput Aided Drug Des; 2022; 18(7):506-518. PubMed ID: 36321226
[TBL] [Abstract][Full Text] [Related]
17. The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Huang WC; Yadav VK; Cheng WH; Wang CH; Hsieh MS; Huang TY; Lin SF; Yeh CT; Kuo KT
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885115
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
20. Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies.
Alrouji M; Benjamin LS; Alhumaydhi FA; Al Abdulmonem W; Baeesa SS; Rehan M; Shahwan M; Shamsi A; Akhtar A
Sci Rep; 2023 Oct; 13(1):17684. PubMed ID: 37848584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
